Tamsulosin: an overview.

Christopher Chapple; Karl-Erik Andersson

doi:10.1007/s00345-002-0246-7

Home/Archive/PubMed

PubMed · 12022708

Tamsulosin: an overview.

Christopher Chapple·Karl-Erik Andersson

View original source ↗Export metadata ↓

Abstract

This article reviews the contemporary literature related to tamsulosin, which is now the most widely used alpha antagonist in treating benign prostatic hyperplasia. The primary emphasis of this article is on the clinical data that exist related to this agent. Currently, there are no adequate studies that effectively compare existing agents for the treatment of benign prostatic hyperplasia using a randomised, placebo-controlled design with adequate numbers and this needs to be addressed in future studies.

Explore related subjects

Adrenergic alpha-Antagonists Aged Dose-Response Relationship, Drug Drug Administration Schedule Europe Follow-Up Studies Humans Japan Male Middle Aged Prostatic Hyperplasia Randomized Controlled Trials as Topic Sulfonamides Tamsulosin Treatment Outcome United States Comparative Study Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Christopher Chapple, Karl-Erik Andersson. 2002. Tamsulosin: an overview.. https://doi.org/10.1007/s00345-002-0246-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Vasodilatation of muscle microvessels induced by somatic afferent stimulation is mediated by calcitonin gene-related peptide release in the rat.

In anesthesized rats, the effects of electrical stimulation (ES) to the saphenous nerve on the microcirculation of the gracilis muscle were assessed through the measurement of two different hemodynamic parameters: (a). the muscle blood flow (MBF) using a laser Doppler flowmeter; and (b). the changes in diameter of the muscle arterioles observed directly using an intravital microscope system. Ipsilateral ES (5 V, 20 Hz, for 30 s) produced increases in MBF and mean arterial pressure (47+/-10% and 18+/-5%) over the baseline, while no significant changes in MBF were observed in the contralateral muscle. Neither selective nor simultaneous alpha- and beta-adrenergic blockade altered the increases in MBF induced by ipsilateral ES. The arteriolar diameter was found to increase by 38.9+/-5% following ipsilateral ES. This response in diameter was abolished after the topical application of a calcitonin gene-related peptide receptor antagonist (CGRP(8-37)). Contralateral ES produced a decrease in arteriolar diameter by 26+/-14%. Thus, ipsilateral nerve ES produced vasodilative responses in the muscle accompanied by increases in MBF independently of the sympathetic activity. Furthermore, CGRP was found directly involved in the reflex neural regulation of the muscle microcirculation, which suggests the participation of an axon reflex mechanism.

Adrenergic alpha-Antagonists↗

PubMed2002

Interaction between alpha2-autoreceptors and receptors mediating the effects of angiotensin II and bradykinin in the heart of newborn rats.

The interaction between alpha2-autoreceptors and receptors for angiotensin II and bradykinin was studied in the heart of newborn rats. The tissues were labelled with [3H]noradrenaline and then superfused with cocaine-containing medium and stimulated electrically. Angiotensin II (10-300 nM) and bradykinin (3-100 nM) enhanced the evoked overflow of tritium, the maximum increase reaching 63.2% and 87.1%, respectively. Blockade of alpha2-adrenoceptors by 100 nM yohimbine reduced, and that by 1 microM abolished, the effect of both angiotensin II and bradykinin. On the contrary, chelerythrine and staurosporine--blockers of protein kinase C--as well as forskolin, an activator of adenylyl cyclase and a blocker of phosphodiesterase, markedly enhanced the facilitatory effect of angiotensin II and bradykinin. We conclude that: (1) alpha2-autoreceptors are present in the heart of newborn rats which interact with prejunctional receptors for angiotensin II and bradykinin also present in the rat heart at that age; (2) the facilitatory influence of chelerythrine and staurosporine on the one hand and that of forskolin on the other hand suggests a link between protein kinase C and cyclicAMP pathways.

Adrenergic alpha-Antagonists↗

PubMed2002

[11C]RN5: a new agent for the in vivo imaging of myocardial alpha1-adrenoceptors.

The radiolabelling with the positron-emitter Carbon-11 and the biological evaluation in rats of 3-[2-[4-(2-[11C]methoxyphenyl)piperazin-1-yl]ethyl]pyrimido[5,4-b]indole-2,4-dione ([11C]RN5), alpha1-adrenoceptor antagonist (K(i)=0.21 nM), as a putative radioligand for the non-invasive assessment of alpha1-adrenoceptors with positron emission tomography (PET) is reported. The radiosynthesis procedure consisted of O-methylation of des-methyl precursor with [11C]methyl iodide in the presence of potassium hydroxide in dimethylformamide (DMF) at 80 degrees C. [11C]RN5 was obtained in >99% radiochemical purity in 25 min with a radiochemical yield in the 20-30% range, end of synthesis (EOS) (non-decay corrected) and a specific radioactivity of 92.5+/-18.5 GBq/micromol. Pre-clinical studies in rats showed a high uptake of [11C]RN5 in heart, spleen, adrenal gland, lung and kidney but not in the brain. Inhibition studies with high doses of different adrenergic antagonists indicate that more than 70% of myocardial uptake of [11C]RN5 is due to specific binding to alpha1-adrenoceptors. Our results indicate that [11C]RN5 is suitable to be further developed as a potential radioligand for the in vivo PET imaging of myocardial alpha1-adrenoceptors in humans.

Adrenergic alpha-Antagonists↗